INTERNATIONAL PATENT: ORIC PHARMACEUTICALS, INC. FILES APPLICATION FOR "TREATMENT OF CANCERS COMPRISING EGFR EXTRACELLULAR AND TRANSMEMBRANE MUTATIONS"

GENEVA, April 20 -- ORIC PHARMACEUTICALS, INC. (240 E. Grand Avenue, Suite 2South San Francisco, California 94080) filed a patent application (PCT/US2025/049635) for "TREATMENT OF CANCERS COMPRISING EGFR EXTRACELLULAR AND TRANSMEMBRANE MUTATIONS" on Oct 06, 2025. With publication no. WO/2026/080372, the details related to the patent application was published on Apr 16, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): DAEMEN, Anneleen (c/o ORIC Pharmaceuticals, Inc.240 E. Grand Avenue, Suite 2South San Francisco, California 94080), JUNTTILA, Melissa R. (c/o ORIC Pharmaceuticals, Inc.240 E. Gra...